Cellectis reported a significantly wider net loss for the nine-month period and is undergoing a strategic shift towards in vivo gene editing, discontinuing two clinical programs. The company's cash runway extends into H2 2028, supported by an operating model realignment, while positive preclinical data for a new candidate offers a future pipeline prospect.
Cellectis reported a net loss of $101.1 million for the nine months ended September 30, 2026, a substantial increase from $41.3 million in the prior year, indicating deteriorating financial performance. The company is undergoing a significant strategic transformation, discontinuing its lasme-cel and eti-cel clinical programs to focus on in vivo gene editing. This pivot, while potentially offering long-term upside with candidates like .HEAL-101, creates short-term uncertainty and reflects a setback for its previous pipeline. The cash runway extending into H2 2028 provides some stability, but the wider loss and program cancellations are likely to be viewed negatively by investors in the short term, impacting CLLS shares. The key opportunity lies in the successful development of its in vivo gene editing pipeline, but this is a long-term prospect with inherent R&D risks.